Purpose of review The role of a re-transurethral resection (TUR) is clearly demonstrated in T1 high-grade nonmuscle invasive bladder cancer. However, its role remains controversial for Ta high-risk tumors and the recent European guidelines stated that the second look procedure could be avoided for these patients despite harboring a high-risk of both disease recurrence and progression. We aimed to evaluate the added benefit on staging, response to bacillus Calmette-Guerin and oncological outcomes of re-TUR in patients with Ta high-grade nonmuscle invasive bladder cancer. Recent findings Overall, we identified 15 studies, including 3912 patients from which 743 harbored Ta high-grade disease. Delay between first and second TUR was ranging from 2 to 12 weeks (median 5.6 weeks). The rate of residual disease was 52.8% (range 17-67%). The rate of overall upstaging to T1 and muscle-invasive disease were 10.9 and 4.7%, respectively. Although there was a trend toward improvement of recurrence-free survival outcomes, no definitive conclusions can be drawn due to the retrospective design of the studies included. Residual tumor is common after initial TUR for Ta high-grade. Re-TUR is useful in reducing the rates of residual disease, may improve staging, response to bacillus Calmette-Guerin and oncological outcomes.

Regnier, S., Califano, G., Elalouf, V., Albisinni, S., Aziz, A., Di Trapani, E., et al. (2022). Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: A systematic review. CURRENT OPINION IN UROLOGY, 32(1), 54-60 [10.1097/MOU.0000000000000949].

Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: A systematic review

Albisinni S.;
2022-01-01

Abstract

Purpose of review The role of a re-transurethral resection (TUR) is clearly demonstrated in T1 high-grade nonmuscle invasive bladder cancer. However, its role remains controversial for Ta high-risk tumors and the recent European guidelines stated that the second look procedure could be avoided for these patients despite harboring a high-risk of both disease recurrence and progression. We aimed to evaluate the added benefit on staging, response to bacillus Calmette-Guerin and oncological outcomes of re-TUR in patients with Ta high-grade nonmuscle invasive bladder cancer. Recent findings Overall, we identified 15 studies, including 3912 patients from which 743 harbored Ta high-grade disease. Delay between first and second TUR was ranging from 2 to 12 weeks (median 5.6 weeks). The rate of residual disease was 52.8% (range 17-67%). The rate of overall upstaging to T1 and muscle-invasive disease were 10.9 and 4.7%, respectively. Although there was a trend toward improvement of recurrence-free survival outcomes, no definitive conclusions can be drawn due to the retrospective design of the studies included. Residual tumor is common after initial TUR for Ta high-grade. Re-TUR is useful in reducing the rates of residual disease, may improve staging, response to bacillus Calmette-Guerin and oncological outcomes.
2022
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/24 - UROLOGIA
English
bacillus Calmette-Guerin
nonmuscle-invasive bladder cancer
re-transurethral resection
second look
Ta high-grade
Regnier, S., Califano, G., Elalouf, V., Albisinni, S., Aziz, A., Di Trapani, E., et al. (2022). Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: A systematic review. CURRENT OPINION IN UROLOGY, 32(1), 54-60 [10.1097/MOU.0000000000000949].
Regnier, S; Califano, G; Elalouf, V; Albisinni, S; Aziz, A; Di Trapani, E; Krajewski, W; Mari, A; D'Andrea, D; Pradere, B; Soria, F; Afferi, L; Moschi...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/310284
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact